Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Average Recommendation of “Hold” from Analysts

Smith & Nephew SNATS, Inc. (NYSE:SNN) has been given an average rating of “Hold” by the twelve ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and one has given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $31.91.

SNN has been the subject of several analyst reports. BTIG Research started coverage on shares of Smith & Nephew SNATS in a research note on Monday, August 31st. They issued a “neutral” rating for the company. Weiss Ratings cut shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. Kepler Capital Markets downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Morgan Stanley lowered shares of Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a research report on Wednesday, September 2nd. Finally, Zacks Research raised shares of Smith & Nephew SNATS from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 8th.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Equity Investment Corp boosted its holdings in shares of Smith & Nephew SNATS by 3.9% during the fourth quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock worth $246,000 after purchasing an additional 285 shares during the last quarter. Cary Street Partners Financial LLC grew its position in shares of Smith & Nephew SNATS by 1.8% in the fourth quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock valued at $665,000 after purchasing an additional 365 shares during the period. Parallel Advisors LLC increased its stake in Smith & Nephew SNATS by 20.0% in the first quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock valued at $74,000 after purchasing an additional 387 shares during the last quarter. Clearstead Trust LLC acquired a new position in Smith & Nephew SNATS in the second quarter valued at $25,000. Finally, BKM Wealth Management LLC increased its stake in Smith & Nephew SNATS by 2.5% in the first quarter. BKM Wealth Management LLC now owns 18,462 shares of the medical equipment provider’s stock valued at $587,000 after purchasing an additional 451 shares during the last quarter. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Price Performance

Shares of NYSE:SNN opened at $26.92 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14. Smith & Nephew SNATS has a 52-week low of $26.40 and a 52-week high of $37.51. The stock’s fifty day simple moving average is $29.32 and its 200-day simple moving average is $30.57.

Smith & Nephew SNATS Announces Dividend

The company also recently announced a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be paid a $0.3120 dividend. This represents a yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company headquartered in the United Kingdom. Founded in 1856 by Thomas James Smith in Hull, the company initially operated as a pharmacy business before expanding into healthcare products and medical devices.

The company develops and manufactures technologies used in orthopaedic reconstruction, sports medicine, and advanced wound management. Its products include joint replacement systems, trauma and extremities devices, arthroscopic equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products designed to support tissue healing and surgical care.

Smith & Nephew serves hospitals, healthcare professionals, and patients in markets around the world.